Probably Genetic Raised $12 Million for Drug Discovery
The firm will expand its AI-driven patient identification platform to drug development following a new funding round.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust AI platforms to accurately identify rare diseases through self-reported health data?
Probably Genetic has raised $12 million in Series A funding, bringing its total capital to $14 million. The company uses an AI platform to integrate patient-reported symptoms and medical records for rare disease identification.
Why it matters
The company intends to use this capital to transition from patient identification into drug discovery. Pharmaceutical partners leverage these data to match specific patients to clinical trials and existing therapies.
The firm has collected data from 130,000 patients to date. Its platform processes self-reported symptoms, medical records, and biological data, with patient copays for testing typically capped at $250.
The players
Probably Genetic
A diagnostic data company that uses AI to identify rare disease patients for clinical trials and pharmaceutical research.
Threshold
A venture capital firm that led the current $12 million Series A funding round for the company.
ARPA-H
The Advanced Research Projects Agency for Health, a federal agency supporting high-risk, high-reward biomedical research.
The details
The platform functions by synthesizing fragmented health data into phenotypic data—information describing an organism's observable characteristics. It relies on a network of pharma partnerships and insurance-billed testing rather than owning physical labs. Sequencing is performed by external partners to scale the collection process.
Timeline
2018: Probably Genetic was founded.
August 2026: Company awarded up to $10 million from ARPA-H.
October 14, 2026: Company announced $12 million series A funding.
2027: Company plans to expand to proteomic testing.
The Tech Race
The company participates in the ARPA-H RAPID program, which coordinates large-scale efforts to accelerate diagnostic pathways. This strategy follows a broader industry trend of diagnostic firms using proprietary datasets to pivot into the higher-margin business of clinical trial recruitment.
The company's diagnostic testing remains available through a mix of pharma-funded and insurance-billed models. Users can expect costs for diagnostic services to remain capped, as the firm continues to prioritize patient enrollment for pharmaceutical research.
The takeaway
The firm is successfully monetizing the diagnostic odyssey by bridging the gap between patient data collection and pharmaceutical R&D pipelines. Stakeholders should monitor the 2027 rollout of proteomic testing as a benchmark for the platform's expanded diagnostic accuracy.
What happens next
The company plans to expand its diagnostic capabilities to include proteomic testing—the large-scale study of proteins—starting in 2027.
Further reading
Learn more about the latest innovations in the Biotech sector.
Source note: This article includes information reported by FierceHealth.
Live Poll
Do you trust AI platforms to accurately identify rare diseases through self-reported health data?
